Vaxart Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Vaxart's estimated annual revenue is currently $4.2M per year.
- Vaxart received $18.4M in venture funding in January 2015.
- Vaxart's estimated revenue per employee is $122,324
- Vaxart's total funding is $58.6M.
- Vaxart has 34 Employees.
- Vaxart grew their employee count by -17% last year.
- Vaxart currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is Vaxart?
Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are prophylactic oral vaccines for seasonal influenza, RSV and norovirus, as well as a therapeutic vaccine for HPV types 16 and 18. Vaxart vaccines are convenient room temperature-stable tablets that are easy to administer, and that eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The company is listed on the NASDAQ exchange under ticker nymbol VXRT.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--. Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant ...
Stock analysts at Brookline Capital Management assumed coverage on shares of Vaxart (NASDAQ:VXRT) in a research note issued on ...
Vaxart (NASDAQ:VXRT) has been given a $2.00 target price by HC Wainwright in a research note issued on Wednesday, August 21st, ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
|2007-11-16||$3.3M||A||Quantum Technology Partners, Life Science Angels||Article|
|2010-03-05||$12.5M||B||Care Capital of Princeton NJ||Article|
Vaxart Executive Hires
|2014-05-09||John M. Harland||CFO||Article|
|2016-02-10||Samir Singh||SVP corporate development and strategy.||Article|
|2018-04-20||Brant Biehn||SVP Commercial Operations||Article|
|2018-05-02||David Taylor||Chief Medical Officer||Article|